Bildkälla: Stockfoto

Cantargia Q2 2024: CAN10 Proof-of-Mechanism - Redeye

Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mechanism established in the single-dose cohorts. The study of nadunolimab in triple-negative breast cancer has been delayed by up to six months with readout now expected by H1 2025.

Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mechanism established in the single-dose cohorts. The study of nadunolimab in triple-negative breast cancer has been delayed by up to six months with readout now expected by H1 2025.
Börsvärldens nyhetsbrev
ANNONSER